Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + ramucirumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of nivolumab, a human IgG4 monoclonal antibody targeting the programmed cell death-1 (PD-1) receptor, and ramucirumab, a human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2). This combination leverages both immune checkpoint inhibition and anti-angiogenesis mechanisms to treat advanced cancers, particularly gastric and esophageal adenocarcinomas.
- Brand names
- OpdivoCyramza
- Other names
- nivolumab plus ramucirumab
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nivolumab + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + ramucirumab.